GlassScriptPhysician profile
Anna Kissin
NPI 1336254762
$13,880.34
in general payments reported to CMS, 2019-2025
68 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $1,561 · 2021: $2,185 · 2022: $2,144 · 2023: $2,066 · 2024: $2,024 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,024 · Education: $131 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,024.21 |
| Education | $130.66 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,995.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,387.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $995.03 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $805.11 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.98 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $511.86 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $399.89 | 2021-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $383.12 | 2019-2022 | |
| Abbvie INC. | $377.38 | 2019-2025 | |
| Pfizer INC. | $345.55 | 2019-2024 | |
| Dexcom, INC. | $323.74 | 2020-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $314.86 | 2019-2025 | Licart, Tirosint, Tirosint |
| Insulet Corporation | $274.58 | 2019-2025 | Omnipod |
| Vivus LLC | $259.32 | 2019-2024 | Qsymia |
| Bayer Healthcare Pharmaceuticals INC. | $245.66 | 2021-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.55 | 2019-2024 | Farxiga |
| Mannkind Corporation | $235.50 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $216.93 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $160.65 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Alexion Pharmaceuticals, INC. | $140.58 | 2020-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $134.35 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.08 | 2019-2024 | Cycloset, Trulance, Xifaxan |
| Corcept Therapeutics | $114.92 | 2023-2025 | Korlym |
| Verity Pharmaceuticals INC. | $114.83 | 2024-2025 | Tlando, Trelstar |
| Radius Health, INC. | $106.17 | 2019-2025 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $102.46 | 2019-2022 | |
| Medtronic, INC. | $91.74 | 2024-2025 | Minimed 780g, Inceptiv |
| Currax Pharmaceuticals LLC | $87.70 | 2019-2025 | Contrave |
| Tandem Diabetes Care, INC. | $86.17 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $80.51 | 2020-2025 | Isturisa, Signifor Lar |
| Tolmar, INC. | $77.98 | 2023-2024 | |
| Madrigal Pharmaceuticals | $76.63 | 2025 | Rezdiffra |
| Kowa Pharmaceuticals America, INC. | $70.87 | 2020-2022 | |
| Eisai INC. | $68.75 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $67.78 | 2023-2025 | Yorvipath |
| Glaxosmithkline, LLC. | $64.33 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $63.88 | 2025 | |
| Beta Bionics, INC. | $62.27 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $60.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $59.48 | 2021-2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $55.60 | 2020-2023 | Crysvita |
| Amryt Pharma Holdings LTD | $54.62 | 2021-2023 | Mycapssa |
| Embecta Corp. | $54.13 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Neurocrine Biosciences, INC. | $50.92 | 2024-2025 | |
| Astellas Pharma US INC | $50.41 | 2019-2024 | Veozah |
| Arbor Pharmaceuticals, INC. | $43.71 | 2020-2022 | |
| Amphastar Pharmaceuticals, INC. | $42.46 | 2024-2025 | |
| Acerus Pharmaceuticals Corporation | $42.41 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $42.18 | 2023 | Edarbi, Adthyza, Edarbyclor |
| Janssen Pharmaceuticals, INC | $41.44 | 2019-2020 | |
| Bausch Health US, LLC | $37.71 | 2020-2021 | |
| Sequel Med Tech, LLC | $35.10 | 2025 | Twiist |
| Averitas Pharma INC. | $33.13 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $31.19 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $29.20 | 2020 | |
| Cequr Corporation | $29.12 | 2022-2025 | Cequr Simplicity |
| Endo Pharmaceuticals INC. | $27.57 | 2021-2022 | |
| Amarin Pharma, INC. | $26.22 | 2019 | |
| Zealand Pharma US, INC. | $25.52 | 2022 | |
| Chiesi USA, INC. | $23.92 | 2025 | Mycapssa |
| Intra-Sana Laboratories | $18.06 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Clarus Therapeutics INC. | $14.96 | 2021 | |
| Echosens North America, INC. | $14.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.63 | 2021 | |
| Becton, Dickinson and Company | $13.60 | 2022 | |
| Shire North American Group INC | $13.52 | 2019 | |
| Boston Scientific Corporation | $13.33 | 2019 | |
| Axsome Therapeutics, INC. | $12.85 | 2023 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kissin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.